APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo (Q34722539)

4 August 2017

APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo (English)

1 reference

4 August 2017

1 reference

8

Michael Weller

1 reference

4 August 2017

7

Wolfgang Wick

1 reference

4 August 2017

6

Ghazaleh Tabatabai

1 reference

4 August 2017

2

Patrick Roth

1 reference

4 August 2017

3

Kathy Hasenbach

1 reference

4 August 2017

4

Steffen Aulwurm

1 reference

4 August 2017

Günter Eisele

1

1 reference

PubMed ID

21183510

4 August 2017

Fabian Wolpert

series ordinal

5

1 reference

4 August 2017

22 December 2010

1 reference

4 August 2017

1 reference

4 August 2017

13

1 reference

4 August 2017

2

1 reference

4 August 2017

155-164

1 reference

Combining radiotherapy with APO010 in cancer treatment

4 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064626

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064626

Death receptors as targets for anti-cancer therapy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064626

Role of full-length osteoprotegerin in tumor cell biology

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064626

Abundant Fas expression by gastrointestinal stromal tumours may serve as a therapeutic target for MegaFasL.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064626

The combination of chemotherapy and intraperitoneal MegaFas Ligand improves treatment of ovarian carcinoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064626

Mechanisms of resistance of human glioma cells to Apo2 ligand/TNF-related apoptosis-inducing ligand

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064626

TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064626

O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064626

A Fas agonist induces high levels of apoptosis in haematological malignancies

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064626

Experimental therapy using interferon-gamma and anti-Fas antibody against oral malignant melanoma cells

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064626

Human malignant glioma cells express semaphorins and their receptors, neuropilins and plexins

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064626

Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064626

Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064626

Caspase-dependent chemotherapy-induced death of glioma cells requires mitochondrial cytochrome c release

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064626

Safety and antitumor activity of recombinant soluble Apo2 ligand

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064626

APO2 ligand: a novel lethal weapon against malignant glioma?

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064626

Immunochemotherapy of malignant glioma: synergistic activity of CD95 ligand and chemotherapeutics.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064626

Lethal effect of the anti-Fas antibody in mice

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064626

Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064626

Monoclonal antibody-mediated tumor regression by induction of apoptosis.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064626

A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064626

Treatment of experimental glioma by administration of adenoviral vectors expressing Fas ligand

7 July 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOQ176

Death receptor-independent cytochrome c release and caspase activation mediate thymidine kinase plus ganciclovir-mediated cytotoxicity in LN-18 and LN-229 human malignant glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOQ176

Inhibition of O6-methylguanine-DNA methyltransferase by glucose-conjugated inhibitors: comparison with nonconjugated inhibitors and effect on fotemustine and temozolomide-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOQ176

Characterization of the integrin alpha v beta3 in arteriovenous malformations and cavernous malformations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOQ176

Expression and biological activity of X-linked inhibitor of apoptosis (XIAP) in human malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOQ176

CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOQ176

Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOQ176

Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064626

Fas/APO-1 gene transfer for human malignant glioma.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064626

Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL)

26 October 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOQ176

Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21183510

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21183510

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Distinct experimental efficacy of anti-Fas/APO-1/CD95 receptor antibody in human tumors

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21183510

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1093/NEUONC/NOQ176

1 reference

4 August 2017

1 reference

4 August 2017

1 reference

PubMed ID

21183510